NO-independent stimulators of soluble guanylate cyclase.
about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.6-Amino-3-methyl-4-(4-nitro-phen-yl)-1-phenyl-pyrazolo[3,4-b]pyridine-5-carbonitrilecGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studiesPharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studiesNO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.Current and future trends in the oral pharmacotherapy of male erectile dysfunction.Carbon monoxide down-regulates α4β1 integrin-specific ligand binding and cell adhesion: a possible mechanism for cell mobilization.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.The future of the oral pharmacotherapy of male erectile dysfunction: things to come.Novel therapies for cyclic GMP control of vascular smooth muscle growthLeads for the treatment of pulmonary hypertension.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Soluble guanylate cyclase: a potential therapeutic target for heart failure.Stimulators of soluble guanylyl cyclase: future clinical indicationsThe chemistry and biology of soluble guanylate cyclase stimulators and activators.Use of ionic liquids as neoteric solvents in the synthesis of fused heterocycles.Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.Metal-free intermolecular formal cycloadditions enable an orthogonal access to nitrogen heterocycles.Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.Soluble guanylate cyclase is activated differently by excess NO and by YC-1: resonance Raman spectroscopic evidence.Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.Soluble guanylate cyclase: an old therapeutic target re-visited.Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase.Meeting report of the 8th International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017.Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines.Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
P2860
Q24656131-37242DB1-448E-49D9-A73D-8AABF7540531Q24798007-94257EDC-6709-4970-BA69-71E6F7F219CCQ27692662-7209AB91-F7F7-4026-B661-E99A1C17B9FBQ33903491-A8CCFCA8-DB3D-4023-9A71-EA9E74F836F7Q34212268-F0E5F169-8905-475F-BD27-3B156F93162AQ34228088-5F590B09-9869-4C3B-B0FC-3970A0D1AE91Q34244951-7693B844-2ADB-43B5-A0FF-ED723B2CBDA7Q34538482-ABEB1F61-C120-468F-B465-782950E8CB52Q35001011-4F18101C-5AA4-4E2B-9F9E-0D5F30A2CE49Q35010064-94ACA802-E257-4696-ABAE-4EDFE3214E0CQ35044037-8847F7D7-F87D-4DFD-9828-02A4BDE16CC4Q35044042-17F21316-469E-48C7-AEF1-E3B6A867C090Q35044464-5AD03A84-E7BF-49DA-B571-F220C759A759Q35206512-40D1008A-A7E3-4BFC-B46F-CA366E55E29CQ35207625-F72F4718-3F60-4D61-9BB6-272DA6CB6584Q35390252-E28DB320-8103-4973-B9F1-946A2AC66153Q35740400-2D52CF6F-39C5-4853-A11F-06244035DB6BQ36866594-29B5906D-AD43-40A7-A536-A15BC48F2547Q37179695-ECAA4AC7-92F0-4262-9F53-FA98A595CCEEQ37481343-D5B064A7-35DB-4101-A9F9-F01E4A256676Q38000562-51D72A0E-7DBF-4958-826B-F31EAD1E0B9AQ38012596-23924079-C3B9-4A42-9967-78AC5443B840Q38093420-83F2B078-D88F-43D7-8106-F8611C5559DDQ38130465-81238CE9-5007-4C91-8F20-2BEF52EFA93CQ38213927-10744A87-FB12-4388-BAC8-8917D3A7D1DDQ38777323-F92E4760-1F64-4CEE-8C33-EDF54E2451EEQ39114187-FD8FAA77-89FE-448A-A631-29219C4FC7A2Q39847509-CD52FD07-C186-4F0E-884D-FF405274767FQ40978111-21629A90-8CF2-47F0-96AB-ACBD88A0A7F5Q41770411-C159FE0C-3ED4-47BC-8AAE-7ABF9BFA4A4AQ41879996-2FAAA6A3-5E16-4BFE-8A71-56F01DB5E295Q43263737-316A0215-C7D6-4F37-9867-8EAAC02A2EBEQ44626758-D7F40628-054B-4DC4-9E59-9757CE132834Q45193709-82EF7F38-50CC-41DD-A1ED-A8843662F1DCQ46712818-83EDA1CF-9C11-4145-9D96-837713A11119Q47313531-A9822D6F-DD64-42C1-88D7-10F5AA0760C9Q47904506-AF6C081B-CC11-4B6A-BD6C-D91C80A1182EQ48632087-9646F776-1B7F-4041-B082-AF71A22A6C12Q49489205-4A864539-96B6-4ADD-8545-D3CD61D761BBQ52738823-E1464361-2D27-4EDC-B11D-5277F4F4CCBC
P2860
NO-independent stimulators of soluble guanylate cyclase.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
NO-independent stimulators of soluble guanylate cyclase.
@en
NO-independent stimulators of soluble guanylate cyclase.
@nl
type
label
NO-independent stimulators of soluble guanylate cyclase.
@en
NO-independent stimulators of soluble guanylate cyclase.
@nl
prefLabel
NO-independent stimulators of soluble guanylate cyclase.
@en
NO-independent stimulators of soluble guanylate cyclase.
@nl
P2093
P1476
NO-independent stimulators of soluble guanylate cyclase.
@en
P2093
Alonso-Alija C
Benet-Buchholz J
Fürstner C
P304
P356
10.1016/S0960-894X(01)00073-7
P407
P577
2001-03-01T00:00:00Z